Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress.
Michelle T LeeDhruv MahttaLouis DlouhyHunaina ShahabMahmoud Al RifaiSalim S ViraniPublished in: Current atherosclerosis reports (2021)
Reviewed studies assess single photon emission computed tomography, positron emission tomography, magnetic resonance imaging in coronary artery disease (PACIFIC-II); empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); dapagliflozin in chronic heart failure (DAPA-HF); proprotein convertase subtilisin/kexin type 9 inhibitor and its lipid lowering effects (NATURE-PCSK9); fixed-dose combination therapies with or without aspirin in primary prevention; overview of contrasting results between REDUCE-IT versus STRENGTH trials; Quadruple UltrA-low-dose tReaTment for hypertension (QUARTET); evolocumab and changes in plaque composition on optical coherence tomography (HUYGENS); and low-dose rivaroxaban during the acute phase of acute coronary syndrome (H-REPLACE). Research presented at the 2021 ESC Congress shows promise in reducing burden of cardiovascular disease and reinforces the value of cardiovascular disease prevention.
Keyphrases
- low dose
- cardiovascular disease
- positron emission tomography
- computed tomography
- coronary artery disease
- acute coronary syndrome
- cardiovascular events
- low density lipoprotein
- high dose
- optical coherence tomography
- percutaneous coronary intervention
- type diabetes
- cardiovascular risk factors
- blood pressure
- magnetic resonance imaging
- pet ct
- pet imaging
- helicobacter pylori
- case control
- atrial fibrillation
- antiplatelet therapy
- helicobacter pylori infection
- risk factors
- magnetic resonance
- image quality
- metabolic syndrome
- artificial intelligence
- ejection fraction
- left ventricular
- deep learning
- mass spectrometry
- acute heart failure
- optic nerve
- cardiac surgery